[13] [14] [15] [26] [36] [15] to reduce excess body weight and maintain weight reduction long term in obese individuals twelve years of age or older, or for overweight adults with at least one weight-related comorbid condition
doi: 10.3389/fcdhc.2023.1293926 Received 13 September 2023 Accepted 16 November 2023 Published 08 December 2023 Volume 4 - 2023 Edited by Azra Durak-Nalbantic, Clinical Center University of Sarajevo, Bosnia and Herzegovina Reviewed by Edin Begic, Sarajevo School of Science and Technology, Bosnia and Herzegovina Updates Copyright 2023 Ferhatbegovi, Mri and Maci-Dankovi
Unpublished results from the first phase II trial with the triple combination of semaglutide, cilofexor and/or firsocostat treatment for 24 weeks in 108 patients with NASH showed significant improvements in hepatic steatosis (measured with MRI) and liver injury (measured by serum alanine aminotransferase) in the combination treatment arm vs semaglutide monotherapy (56)
Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor
While still emerging, this technology could eventually offer weekly or even less frequent application schedules
Kirkpatrick A, Heo J, Abrol R, Goddard WA: Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor
